Fintel reports that on October 27, 2025, Needham reiterated coverage of Fate Therapeutics (NasdaqGM:FATE) with a Hold recommendation. Analyst Price Forecast Suggests 175.09% Upside As of September 30, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results